For the first time since 2011, a US Food and Drug Administration advisory committee will consider whether an accelerated approval drug should continue to be marketed given the failure of a postmarketing trial to verify clinical benefit.
On 29 October, the agency’s Bone, Reproductive and Urologic Drugs Advisory Committee will re-evaluate the regulatory status of AMAG...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?